Jacobs Levy Equity Management Inc. Has $999,000 Holdings in Bioventus Inc. $BVS

Jacobs Levy Equity Management Inc. lessened its holdings in Bioventus Inc. (NYSE:BVS) by 36.4% during the first quarter, HoldingsChannel reports. The fund owned 109,215 shares of the company’s stock after selling 62,447 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Bioventus were worth $999,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nantahala Capital Management LLC raised its holdings in shares of Bioventus by 2.5% in the 1st quarter. Nantahala Capital Management LLC now owns 4,125,650 shares of the company’s stock worth $37,750,000 after acquiring an additional 98,841 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Bioventus by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 2,554,224 shares of the company’s stock worth $23,371,000 after acquiring an additional 92,143 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Bioventus by 29.1% in the 1st quarter. Driehaus Capital Management LLC now owns 1,445,257 shares of the company’s stock worth $13,224,000 after acquiring an additional 325,402 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Bioventus by 18.0% in the 1st quarter. American Century Companies Inc. now owns 1,044,212 shares of the company’s stock worth $9,555,000 after acquiring an additional 159,539 shares during the last quarter. Finally, Royce & Associates LP raised its holdings in shares of Bioventus by 21.8% in the 1st quarter. Royce & Associates LP now owns 892,216 shares of the company’s stock worth $8,164,000 after acquiring an additional 159,980 shares during the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Bioventus Trading Up 4.0%

Shares of BVS stock opened at $7.28 on Friday. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a 50-day simple moving average of $6.96 and a two-hundred day simple moving average of $7.50. The company has a market capitalization of $601.90 million, a price-to-earnings ratio of -11.93 and a beta of 0.84.

Analyst Ratings Changes

Separately, Cantor Fitzgerald initiated coverage on shares of Bioventus in a report on Monday, July 7th. They issued an “overweight” rating and a $12.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.75.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.